Dance Fever: A Recap of Recent BPCIA Litigation

With the Supreme Court’s pending decision in Sandoz v. Amgen, the interpretation of the patent dance provisions of the BPCIA has been a hot topic here on the blog.  For an in-depth analysis of patent dance strategies employed by biosimilar applicants to date, check out this article in Bloomberg’s Life Sciences Law & Industry Report written by BMW editors Alexandra Valenti, Alexandra Lu, Elaine Blais, and Rob Cerwinski.